Jasper Therapeutics, Inc. (NasdaqCM: JSPR)
Health Care · Biotechnology · US
$0.72
-9.38% today · -75.8% 1Y
Jasper Therapeutics, Inc. (NasdaqCM: JSPR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $23.82M and employs 22 people.
Over the last twelve months the share price has lost 75.8%, trading between 0.32 and 3.05.
Tweenvest scores Jasper Therapeutics, Inc. across four factors: quality 24/100. Its strongest factor is quality.
JSPR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $23.82M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.23
- Dividend yield
- —
- Beta (5Y)
- 3.03
- 52-week high
- $3.05
- 52-week low
- $0.32
- Avg volume (3M)
- —
- Shares outstanding
- 33.27M
- Employees
- 22
- Next earnings
- —
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
- Founded
- 2018
- Listed since
- Jan 10, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.40 | +0.54% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.81 | +0.11% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.97 | +0.58% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.19 | +0.03% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $835.00 | +0.12% |
| argenx SEENXTBR: ARGX | $65.85B | €877.20 | -2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.70 | -0.94% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.